HRP20171749T1 - Protutijela specifična za claudin 6 (cldn6) - Google Patents

Protutijela specifična za claudin 6 (cldn6) Download PDF

Info

Publication number
HRP20171749T1
HRP20171749T1 HRP20171749TT HRP20171749T HRP20171749T1 HR P20171749 T1 HRP20171749 T1 HR P20171749T1 HR P20171749T T HRP20171749T T HR P20171749TT HR P20171749 T HRP20171749 T HR P20171749T HR P20171749 T1 HRP20171749 T1 HR P20171749T1
Authority
HR
Croatia
Prior art keywords
seq
identified
amino acid
acid sequence
antibody
Prior art date
Application number
HRP20171749TT
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Michael Koslowski
Korden Walter
Stefan WÖLL
Maria Kreuzberg
Bernd Hubner
Michael Erdeljan
Original Assignee
Ganymed Pharmaceuticals Gmbh
Johannes Gutenberg-Universität Mainz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09014136A external-priority patent/EP2322555A1/en
Application filed by Ganymed Pharmaceuticals Gmbh, Johannes Gutenberg-Universität Mainz filed Critical Ganymed Pharmaceuticals Gmbh
Publication of HRP20171749T1 publication Critical patent/HRP20171749T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Claims (16)

1. Protutijelo sposobno vezati CLDN6, poželjno CLDN povezano s površinom stanice koju izražava CLDN6, te je sposoban razlikovati CLDN6 na površini stanice koja izražava CLDN6 i CLDN6 mutanta na površini stanice koja izražava navedeni CLDN6 mutant, naznačeno time da CLDN6 mutant obuhvaća mutaciju alalnina na položaju 35, 37 ili 39 aminokiselinske sekvence SEQ ID NO: 2 ili SEQ ID NO: 8, i gdje protutijelo sadrži teški lanac protutijela koji sadrži CDR3 sekvencu teškog lanca protutijela odabranu iz skupine koja se sastoji od ARDYGYVLDY identificiranog unutar SEQ ID NO: 34, ARDYGFVLDY identificiranog unutar SEQ ID NO: 36, ARDFGYVLDY identificirane unutar SEQ ID NO: 38 i ARDYGYVFDY identificirane unutar SEQ ID NO: 40.
2. Protutijelo sukladno patentnom zahtjevu 1, što nije bitno da se veže za CLDN9 povezanu s površinom stanice koja izražava CLDN9.
3. Protutijelo sukladno patentnom zahtjevu 1 ili 2, što nije bitno da se veže za CLDN4 povezanu s površinom stanice koja izražava CLDN4 i/ili nije bitno da se veže za CLDN3 povezanu s površinom stanice koja izražava CLDN3.
4. Protutijelo sukladno bilo kojem od patentnih zahtjeva 1-3, naznačeno time stoje specifično za CLDN6.
5. Protutijelo sukladno bilo kojem od patentnih zahtjeva 1 -4, naznačeno time što je sposobno vezati se za epitop smješten unutar izvanstaničnog dijela CLDN6, pri čemu se spomenuti izvanstanični dio CLDN6 preferirano sadrži sekvencu aminokiselina SEQ ID NO: 6 ili SEQ ID NO: 7.
6. Protutijelo sukladno bilo kojem od patentnih zahtjeva 1-5, naznačeno time da CLDN6 ima aminokiselinsku sekvencu SEQ ID NO: 2 ili aminokiselinsku sekvencu SEQ ID NO: 8.
7. Protmijelo sukladno bilo kojem od patentnih zahtjeva 1-6, koje ima jednu ili više od slijedećih aktivnosti: (i) ubijanje stanica koja eksprimira CLDN6, (ii) inhibiciju proliferacije stanica koja eksprimira CLDN6, (iii) inhibiranje stvaranja kolonija stanica koje eksprimiraju CLDN6, (iv) posredovanje u remisiji utvrđenih tumora, (v) sprječavanje stvaranja i ponovnog stvaranja tumora, i (vi) inhibicija metastaza stanica koje eksprimiraju CLDN6. i/ili koje pokazuje jednu ili više imunološkog efektora protiv stanice koja nosi CLDN6 u svojoj prirodnoj konformaciji, pri čemu je jedna ili više funkcija imunog efektora preferirano odabrana iz skupine koja se sastoji od komplemenata citotoksičnosti (CDC), stanično posredovane citotoksičnosti ovisne o antitijelu (ADCC), indukcije apoptoze, i inhibicije proliferacije, poželjno efektorske funkcije ADCC i/ili CDC.
8. Protutijelo sukladno bilo kojem od patentnih zahtjeva 1-7, koje je monoklonsko, kimerno, humano ili humanizirano protutijelo, ili fragment protutijela.
9. Protutijelo odabrano iz skupine koja se sastoji od (i) protutijela proizvedenog ili koje se može dobiti od klona deponiranog pod pristupnim br. DSM ACC3067 (GT512muMAB 59A), DSM ACC3068 (GT512muMAB 60A), DSM ACC3069 (GT512muMAB 61D), DSM ACC3070 (GT512muMAB 64A), DSM ACC3071 (GT512muMAB 65A), DSM ACC3072 (GT512muMAB 66B), DSM ACC3073 (GT512muMAB 67A), DSM ACC3089 (GT512muMAB 55A), ili DSM ACC3G90 (GT512muMAB 89A), (ii) protutijela koje je kimerizirano ili humanizirano oblik protutijela pod (i), i (iii) protutijela koje sadrži antigen vezujući dio ili antigen vezujuće mjesto protutijela pod (i) naznačeno time što sadrži set HCDRs i LCDRs odabran iz skupine koja se sastoji od (a) HCDR1 aminokiselinske sekvence GYSFTGYT identificirane unutar SEQIDNO: 34, HCDR2 aminokiselinske sekvence INPYNGGT identificirane unutar SEQID NO: 34, HCDR3 aminokiselinske sekvence ARDYGYVLDY identificirane unutar SEQ ID NO: 34, LCDR1 aminokiselinske sekvence SSVSY identificirane unutar SEQ ID NO: 35, LCDR2 aminokiselinske sekvence STS identificirane unutar SEQ ID NO: 35, i LCDR3 aminokiselinske sekvence QQRSIYPPWT identificirane unutar SEQ ID NO: 35; (b) HCDR1 aminokiselinske sekvence GYSFTGYT identificirane unutar SEQ ID NO: 36, HCDR2 aminokiselinske sekvence INPYNGGT identificirane unutar SEQ ID NO: 36, HCDR3 aminokiselinske sekvence ARDYGFVLDY identificirane unutar SEQ ID NO: 36, LCDR1 aminokiselinske sekvence SSVSY identificirane unutar SEQ ID NO: 37, LCDR2 aminokiselinske sekvence STS identificirane unutar SEQ ID NO: 37, i LCDR3 aminokiselinske sekvence QQRSNYPPWT identificirane unutar SEQ ID NO: 37; (c) HCDR1 aminokiselinske sekvence GYSFTGYT identificirane unutar SEQ ID NO: 38, HCDR2 aminokiselinske sekvence INPYNGGI identificirane unutar SEQ ID NO: 38, HCDR3 aminokiselinske sekvence ARDFGYVLDY identificirane unutar SEQ ID NO: 38, LCDRI aminokiselinske sekvence SSVSY identifikovane unutar SEQ ID NO: 39, LCDR2 aminokiselinske sekvence STS identificirane unutar SEQ ID NO: 39, i LCDR3 aminokiselinske sekvence QQRSTYPPWT identificirane unutar SEQ ID NO: 39; i (d) HCDR1 aminokiselinske sekvence GYSFTGYT identificirane unutar SEQ ID NO: 40, HCDR2 aminokiselinske sekvence INPYNGGS identificirane unutar SEQ ID NO: 40, HCDR3 aminokiselinske sekvence ARDYGYVFDY identificirane unutar SEQ IDNO: 40, LCDRI aminokiselinske sekvence SSVNY identificirane unutar SEQ ID NO: 41, LCDR2 aminokiselinske sekvence STS identificirane unutar SEQ ID NO: 41, i LCDR3 aminokiselinske sekvence QQRNNYPPWT identificirane unutar SEQ IDNO: 41.
10. Hibridoma sposoban za proizvodnju protutijela sukladno bilo kojem patentnih zahtjeva 1-9.
11. Hibridoma deponiran pod pristupnim br. DSM ACC3067 (GT512muMAB 59A), DSM ACC3068 (GT512muMAB 60A), DSM ACC3069 (GT512muMAB 61D), DSM ACC3070 (GT512muMAB 64A), DSM ACC3071 (GT512muMAB 65A), DSM ACC3072 (GT512muMAB 66B), DSM ACC3073 (GT512muMAB 67A), DSM ACC3089 (GT512muMAB 55A), ili DSM ACC3090 (GT512rnuMAB 89A).
12. Konjugat koji sadrži protutijelo sukladno bilo kojem od patentnih zahtjeva 1-9 povezano s terapijskim sredstvom, naznačeno time što je terapijsko sredstvo poželjno toksin, radioizotop, lijek ili citotoksični agens.
13. Farmaceutska kompozicija koja sadrži protutijelo sukladno bilo kojem od patentnih zahtjeva 1-9 i/ili konjugat sukladno patentnom zahtjevu 12, i farmaceutski prihvatljivi nosač.
14. ProrutijeJo sukladno bilo kojem od patentnih zahtjeva ]-9 i/iJi konjugat sukladno patentnom zahtjevu 12 za upotrebu u postupku inhibiranja rasta, ubijanja ili inhibiranja metastatskog širenja stanice koja izražava CLDN6 i koja je naznačena time daje CLDN6 asociran s njenom staničnom površinom, koji sadrži dovođenje u kontakt stanice s protutijelom i/ili konjugatom.
15. Protutijelo sukladno bilo kojem od patentnih zahtjeva 1-9, konjugat sukladno patentnom zahtjevu 12 ili farmaceutski pripravak sukladno patentnom zahtjevu 13 za upotrebu u postupku liječenja ili prevencije bolesti ili poremećaja koji uključuje stanicu i koja je karakterizirana udruživanjem CLDN6 sa svojom površinom stanice.u subjektu.
16. Protutijelo, konjugat ili farmaceutski sastav za upotrebu sukladno patentnom zahtjevu 15, naznačeno time da je bolest ili poremećaj povezana s tumorom kao što je karcinom, pri čemu je karcinom poželjno odabran iz skupine koju čine karcinom jajnika, naročito adenokarcinoma jajnika i teratokarcinoma jajnika, karcinom pluća, uključujući i mali (SCLC) i karcinom pluća ne-malih stanica (NSCLC), posebno karcinom pluća skvamoznih stanica i adenokarcinom, karcinom želuca, karcinom dojke, karcinom jetre, karcinom pankreasa, karcinom kože, naročito karcinom bazalnih satanica i karcinom skvamoznih stanica, malignog melanoma, karcinom glave i vrata, posebno malignog pleomorfhi adenom, sarkom, posebno sinovijalnog sarkoma i karcinosarkoma, karcinom žučnog kanala, karcinom mokraćnog mjehura, posebno karcinoma prelaznih stanica i papilarnog karcinoma, karcinom bubrega, posebno karcinom bubrežnih stanica uključujući karcinom jasnih stanica i papilamog carcinoma bubrežnih stanica, karcinom debelog crijeva, karcinom tankog crijeva, uključujući karcinom ileuma, posebno adenokarcinom tankog crijeva i adenokarcinom ileuma, testikularnog embrionalnog karcinoma, placentalnog koriokarcinoma, karcinom cerviksa, rak testisa, posebno testikularnog seminoma, testikularnog teratoma i embrijskog raka testisa, karcinom maternice, tumor zametnutih stanica kao što je teratokarcinom ili embrijski karcinom, posebno tumor zametnutih stanica testisa, i njihovi metastatski oblici.
HRP20171749TT 2009-11-11 2017-11-14 Protutijela specifična za claudin 6 (cldn6) HRP20171749T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26020209P 2009-11-11 2009-11-11
EP09014136A EP2322555A1 (en) 2009-11-11 2009-11-11 Antibodies specific for claudin 6 (CLDN6)
US36161810P 2010-07-06 2010-07-06
EP10006956 2010-07-06
PCT/EP2010/006888 WO2011057788A1 (en) 2009-11-11 2010-11-11 Antibodies specific for claudin 6 (cldn6)
EP10778877.0A EP2499161B8 (en) 2009-11-11 2010-11-11 Antibodies specific for claudin 6 (CLDN6)

Publications (1)

Publication Number Publication Date
HRP20171749T1 true HRP20171749T1 (hr) 2018-01-26

Family

ID=43480734

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171749TT HRP20171749T1 (hr) 2009-11-11 2017-11-14 Protutijela specifična za claudin 6 (cldn6)
HRP20200591TT HRP20200591T1 (hr) 2009-11-11 2020-04-14 Protutijela specifična za klaudin 6 (cldn6)

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20200591TT HRP20200591T1 (hr) 2009-11-11 2020-04-14 Protutijela specifična za klaudin 6 (cldn6)

Country Status (29)

Country Link
US (5) US9487584B2 (hr)
EP (3) EP2499161B8 (hr)
JP (3) JP5889196B2 (hr)
KR (4) KR102317098B1 (hr)
CN (4) CN106432500B (hr)
AU (3) AU2010318316B2 (hr)
BR (1) BR112012011143B1 (hr)
CA (2) CA2775373C (hr)
CY (2) CY1120300T1 (hr)
DK (2) DK3305813T3 (hr)
ES (2) ES2649389T3 (hr)
HK (1) HK1253300A1 (hr)
HR (2) HRP20171749T1 (hr)
HU (2) HUE049404T2 (hr)
IL (2) IL218628B (hr)
LT (2) LT2499161T (hr)
ME (1) ME02943B (hr)
MX (2) MX347150B (hr)
NO (1) NO2499161T3 (hr)
NZ (2) NZ734307A (hr)
PL (2) PL3305813T3 (hr)
PT (2) PT2499161T (hr)
RS (2) RS60168B1 (hr)
RU (1) RU2675997C2 (hr)
SG (2) SG10201500975YA (hr)
SI (2) SI2499161T1 (hr)
UA (1) UA117799C2 (hr)
WO (1) WO2011057788A1 (hr)
ZA (1) ZA201202418B (hr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
LT2398902T (lt) 2009-02-20 2023-12-27 Astellas Pharma Inc. Vėžio diagnostikos ir gydymo būdai bei kompozicijos
LT2499161T (lt) 2009-11-11 2017-11-27 Ganymed Pharmaceuticals Gmbh Specifiniai antikūnai, skirti klaudinui 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
LT3026064T (lt) * 2011-05-13 2019-01-25 Ganymed Pharmaceuticals Gmbh Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6
SG10201911551RA (en) * 2011-05-13 2020-02-27 Ganymed Pharmaceuticals Gmbh Antibodies for treatment of cancer expressing claudin 6
CN103320381B (zh) * 2012-03-23 2015-04-15 上海市儿童医院 一种多能干细胞表面标志物及其用途
MY181648A (en) 2012-08-24 2020-12-30 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
BR122020024124B1 (pt) * 2012-11-13 2024-01-30 Biontech Ag Agentes para tratamento de doenças cancerosas expressando claudina
MX369276B (es) * 2012-11-13 2019-11-04 Biontech Ag Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
EP3747465A1 (en) * 2013-07-31 2020-12-09 BioNTech AG Diagnosis and therapy of cancer involving cancer stem cells
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CN105813650A (zh) * 2013-11-06 2016-07-27 施特姆森特克斯股份有限公司 新型抗-密蛋白抗体和使用方法
CN113307873A (zh) 2013-11-11 2021-08-27 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
AU2015239683B2 (en) * 2014-04-01 2019-08-22 Astellas Pharma Inc. Claudin-6-Specific immunoreceptors and T cell epitopes
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
TWI831044B (zh) 2014-11-11 2024-02-01 日商中外製藥股份有限公司 抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
JP6900051B2 (ja) * 2016-12-07 2021-07-07 国立大学法人大阪大学 Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
CN110612310B (zh) 2017-05-08 2023-06-27 国立大学法人大阪大学 抗cldn-5抗体及含有该抗体的药物
WO2019048040A1 (en) * 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
CN116999573A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体－药物偶联物及其制造方法、药物组合物及其在制备***的药物中的应用
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
EP3735463A4 (en) * 2018-01-05 2022-03-02 Chugai Seiyaku Kabushiki Kaisha THERAPEUTIC AGENT INDUCING CYTOTOXICITY
WO2020075325A1 (ja) * 2018-10-09 2020-04-16 公立大学法人福島県立医科大学 子宮体癌患者の予後予測バイオマーカー
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
KR20210143237A (ko) 2019-03-25 2021-11-26 다이이찌 산쿄 가부시키가이샤 항체-피롤로벤조디아제핀 유도체 컨쥬게이트
BR112021023173A2 (pt) * 2019-07-10 2022-01-04 Chugai Pharmaceutical Co Ltd Moléculas de ligação à claudin-6 e usos das mesmas
CN111087465B (zh) * 2019-12-24 2020-12-08 广州医科大学 一种针对密蛋白6的抗体偶联药物及应用
IL296478A (en) 2020-03-31 2022-11-01 Chugai Pharmaceutical Co Ltd Claudin-6-targeted multispecific antigen-binding molecules and uses thereof
US20240150455A1 (en) * 2021-03-05 2024-05-09 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn6 antibody and use thereof
CA3212665A1 (en) * 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2023053282A1 (ja) 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
WO2024022512A1 (en) * 2022-07-29 2024-02-01 Nanjing Legend Biotech Co., Ltd. Claudin-6 binding moieties and uses thereof
CN116064622B (zh) * 2023-02-13 2023-10-13 优睿赛思(武汉)生物科技有限公司 Claudin6-mCherry报告基因CHO-K1稳转细胞株制备及应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
JP2003524384A (ja) * 1998-11-03 2003-08-19 アドヘレックス テクノロジーズ インコーポレイテッド クラウディン媒介機能を調節するための化合物および方法
JP2002532083A (ja) 1998-12-17 2002-10-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４７個のヒト分泌タンパク質
AU3479700A (en) 1999-02-22 2000-09-14 Incyte Pharmaceuticals, Inc. Genes associated with diseases of the colon
CA2373915A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
WO2001003734A1 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Blocking immune response to a foreign antigen using an antagonist which binds to cd20
WO2001053312A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001236470A1 (en) 2000-01-14 2001-07-24 Corixa Corporation Ovarian tumor-associated sequences
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1309620A2 (en) 2000-06-23 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2416456A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2634294A1 (en) 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
ATE378403T1 (de) 2000-11-30 2007-11-15 Medarex Inc Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002102854A2 (en) * 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
CA2379661A1 (en) * 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2330130B1 (en) 2002-10-17 2014-08-27 Genmab A/S Human monoclonal antibodies against CD20
EP1578996A4 (en) 2002-10-18 2007-12-19 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
WO2006033664A1 (en) 2004-03-08 2006-03-30 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US8450464B2 (en) * 2006-10-02 2013-05-28 Medarex, Inc. Human monoclonal antibodies that bind CXCR4
US8129502B2 (en) * 2006-11-13 2012-03-06 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) * 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CN101918450A (zh) * 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
EP2285392A4 (en) 2008-04-11 2012-06-06 Bionovo Inc PROCEDURE AGAINST CANCER WITH EXTRACTS FROM GLEDITSIA SINENSIS LAM
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
DE102009026966A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Betrieb eines Bremskraftverstärkers als Pedalsimulator
LT2398902T (lt) 2009-02-20 2023-12-27 Astellas Pharma Inc. Vėžio diagnostikos ir gydymo būdai bei kompozicijos
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
LT2499161T (lt) * 2009-11-11 2017-11-27 Ganymed Pharmaceuticals Gmbh Specifiniai antikūnai, skirti klaudinui 6 (cldn6)
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
LT3026064T (lt) 2011-05-13 2019-01-25 Ganymed Pharmaceuticals Gmbh Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen für gynäkologisches Malignom und deren Verwendung
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
MX369276B (es) * 2012-11-13 2019-11-04 Biontech Ag Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
AU2015239683B2 (en) * 2014-04-01 2019-08-22 Astellas Pharma Inc. Claudin-6-Specific immunoreceptors and T cell epitopes

Also Published As

Publication number Publication date
US20240092896A1 (en) 2024-03-21
LT2499161T (lt) 2017-11-27
US10745477B2 (en) 2020-08-18
ME02943B (me) 2018-10-20
CA2775373C (en) 2019-10-29
HK1253300A1 (zh) 2019-06-14
HUE049404T2 (hu) 2020-09-28
MX2020011790A (es) 2020-11-24
DK3305813T3 (da) 2020-04-20
AU2018201640B2 (en) 2020-04-30
RU2012123995A (ru) 2013-12-20
US9932401B2 (en) 2018-04-03
NZ734307A (en) 2020-05-29
KR20210130250A (ko) 2021-10-29
CN106432500A (zh) 2017-02-22
CN102741289B (zh) 2016-08-03
US20200339677A1 (en) 2020-10-29
US20180162938A1 (en) 2018-06-14
WO2011057788A1 (en) 2011-05-19
IL218628A0 (en) 2012-05-31
ES2649389T3 (es) 2018-01-11
IL218628B (en) 2018-12-31
SG10202110692WA (en) 2021-12-30
EP3305813B1 (en) 2020-01-15
BR112012011143B1 (pt) 2020-05-19
ES2784483T3 (es) 2020-09-28
CN105348389A (zh) 2016-02-24
CY1123192T1 (el) 2021-10-29
CN106432500B (zh) 2020-06-02
CN111875703A (zh) 2020-11-03
AU2010318316A1 (en) 2012-04-26
KR20190031335A (ko) 2019-03-25
HUE035516T2 (en) 2018-05-28
PL3305813T3 (pl) 2021-04-19
CN105348389B (zh) 2019-12-20
DK2499161T3 (da) 2017-11-27
KR20120115226A (ko) 2012-10-17
US11858988B2 (en) 2024-01-02
EP3689911A1 (en) 2020-08-05
MX347150B (es) 2017-04-17
AU2018201640A1 (en) 2018-04-05
KR101960509B1 (ko) 2019-03-20
EP2499161B8 (en) 2017-10-25
JP5889196B2 (ja) 2016-03-22
UA117799C2 (uk) 2018-10-10
CA3050655A1 (en) 2011-05-19
JP2016047845A (ja) 2016-04-07
JP2013510808A (ja) 2013-03-28
RS60168B1 (sr) 2020-05-29
RU2675997C2 (ru) 2018-12-25
JP2017140041A (ja) 2017-08-17
SI3305813T1 (sl) 2020-07-31
KR102317098B1 (ko) 2021-10-25
US9487584B2 (en) 2016-11-08
KR20200075903A (ko) 2020-06-26
US20160222125A1 (en) 2016-08-04
ZA201202418B (en) 2013-06-26
PT2499161T (pt) 2017-12-05
HRP20200591T1 (hr) 2020-07-10
EP2499161A1 (en) 2012-09-19
CN102741289A (zh) 2012-10-17
SI2499161T1 (sl) 2017-12-29
AU2016202235B2 (en) 2017-12-07
CY1120300T1 (el) 2019-07-10
KR102126964B1 (ko) 2020-06-25
US20120308478A1 (en) 2012-12-06
AU2010318316B2 (en) 2016-01-14
LT3305813T (lt) 2020-05-11
NO2499161T3 (hr) 2018-02-03
PT3305813T (pt) 2020-04-22
IL246710A0 (en) 2016-08-31
NZ716587A (en) 2017-10-27
MX2012005444A (es) 2012-06-19
JP6125604B2 (ja) 2017-05-10
JP6502992B2 (ja) 2019-04-17
PL2499161T3 (pl) 2018-03-30
IL246710B (en) 2020-05-31
RS56502B1 (sr) 2018-02-28
SG10201500975YA (en) 2015-04-29
EP3305813A1 (en) 2018-04-11
EP2499161B1 (en) 2017-09-06
CA2775373A1 (en) 2011-05-19
BR112012011143A2 (pt) 2016-11-29

Similar Documents

Publication Publication Date Title
HRP20171749T1 (hr) Protutijela specifična za claudin 6 (cldn6)
US11680108B2 (en) Anti-ErbB3 antibodies
HRP20160212T1 (hr) Antitijela za terapiju kancera koji eksprimira klaudin 6
JP2023113893A5 (hr)
JP2020528750A5 (hr)
HRP20201595T1 (hr) Anti-pd-l1 protutijela i njihova uporaba
JP2016047845A5 (hr)
RU2018145852A (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
JP2020510422A5 (hr)
JP2018536624A5 (hr)
RU2020111366A (ru) Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
HRP20150965T1 (hr) Anti-fgr3 protutijela i metode koje ih koriste
JP2017534256A5 (hr)
RU2013104830A (ru) Лечение рака при помощи направленных на мишень антител in vivo
HRP20160584T1 (hr) Novo anti-dr5 antitijelo
AU2024201029A1 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
JP2014531201A5 (hr)
US8603478B2 (en) Anti-RON antibodies
JP2008537673A5 (hr)
JP2014509835A5 (hr)
JP2016536020A5 (hr)
JP2012502938A5 (hr)
JP2010509931A5 (hr)
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2015530989A5 (hr)